Good
Mostly Aligned
Patient Risk:
Moderate
Summary
The AI-generated claims largely reflect approved indications (epilepsy as adjunctive therapy and fibromyalgia) but include several unsupported or misleading statements (e.g., anxiety indication, athletic/sports use, broad drug interactions). It correctly notes withdrawal risk but includes claims about abuse/dependence with partial support. Overall, mixture of correct, unsupported, and contradicted statements yields a Good alignment with notable gaps.
Category Scores
Accurate Statements
Epilepsy (adjunctive therapy for partial-onset seizures) and fibromyalgia are indications.
2.4, 2.5
Withdrawal symptoms can occur after abrupt discontinuation; tapering over at least 1 week is recommended.
5.6
Abuse and dependence potential has been described in labeling.
9.2
Controlled studies show some euphoria as an adverse reaction in some populations.
9.2
Unsupported Statements
Pregabalin is a medication primarily used to treat epilepsy, fibromyalgia, and anxiety disorders.
Anxiety disorder indication is not listed in the provided label sections; only epilepsy (adjunctive) and fibromyalgia are indicated.
Pregabalin is increasingly being found in the athletic community, often in conjunction with other substances, to facilitate recovery.
No label information about athletic use, recovery, or sports-related misuse.
Pregabalin is increasingly being found in the athletic community, often in conjunction with other substances, to enhance performance.
No label information about athletic performance enhancement.
When combined with other substances, pregabalin can interact with various medications.
Label indicates minimal pharmacokinetic interactions with certain drugs; broad 'interact with various medications' is not supported.
When combined with other substances, pregabalin can increase the risk of adverse effects.
Label does not explicitly state increased adverse effects due to interactions; safety data are general.
The combination of pregabalin and stimulants may lead to increased heart rate.
No stimulant-specific interaction data described in provided sections.
The combination of pregabalin and stimulants may lead to increased blood pressure.
No stimulant-specific interaction data described in provided sections.
The combination of pregabalin and stimulants may lead to increased anxiety.
No stimulant-specific interaction data described in provided sections.
Pregabalin can be used as a performance-enhancing agent to suppress pain.
No indication of pain-related performance enhancement in the provided label sections.
Pregabalin can be used as a performance-enhancing agent to suppress muscle cramps.
No indication of performance-enhancing use for cramps in the provided label sections.
WADA has included pregabalin in its prohibited list, effective from 2017.
No WADA listing information is present in the provided label sections.
This ruling prohibits its use by athletes competing in Olympic sports.
No Olympic-sport-specific prohibition information is present in the provided label sections.
WADA's listing indicates concerns regarding pregabalin's potential for abuse and performance enhancement.
No WADA listing information is present in the provided label sections.
Combining lyrica (pregabalin) with other performance-enhancing substances is not a safe practice.
No such warning is present in the provided label sections.
Combining lyrica (pregabalin) with other performance-enhancing substances can lead to adverse interactions.
No information about interactions with performance-enhancing substances in the provided label sections.
Combining lyrica (pregabalin) with other performance-enhancing substances can lead to increased risk of addiction.
No such warning is present in the provided label sections.
Combining lyrica (pregabalin) with other performance-enhancing substances can lead to potential health complications.
No such warning is present in the provided label sections.
Contradictions
Low
AI Statement
When combined with other substances, pregabalin can interact with various medications.
Label Reference
7
Important Omissions
No dosage or administration details discussed in claims; no explicit mention of administration schedule.
Importance:
Moderate
No explicit mention of anxiety disorder indication; no WADA/Olympic-sport-specific information.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Claims about abuse potential and withdrawal risk are present in the label; athletic/sports-use claims are unsupported. Overall patient risk from misinterpretation appears moderate due to potential for misuse and withdrawal considerations.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Some claims are unsupported or mischaracterize label indications (anxiety indication, athletic/sport-use, broad drug interactions).
Suggested Improvement
Limit statements to FDA-approved indications (epilepsy as adjunctive therapy; fibromyalgia) and known safety/abuse data (withdrawal, dependence). Remove or clearly qualify statements about athletic use, performance enhancement, and broad interactions; reference WADA if discussing sports authorities only when labeled information is provided.